2025
83-OR: GLP-1RA Efficacy Doubled with Small Molecule Modulators of Pyruvate Kinase for Obesity Treatment
KIBBEY R, CARDONE R, RUZ-MALDONADO I, ZHAO X, BROWN S, FOSTER H, MERRINS M. 83-OR: GLP-1RA Efficacy Doubled with Small Molecule Modulators of Pyruvate Kinase for Obesity Treatment. Diabetes 2025, 74 DOI: 10.2337/db25-83-or.Peer-Reviewed Original ResearchGLP-1 RAsLean massCombo groupInsulin secretionOptimal treatment of obesityPreservation of lean massObesity treatmentTreatment groupsIslet healthCa2+ oscillationsCa2+ imagingFasting glucose levelsC57BL/6J male miceTreatment of obesityImproved insulin sensitivityGLP-1RAAUC glucoseOptimal treatmentDIO miceMale miceStudy endPlaceboGLP-1Body compositionInsulin sensitivity
2023
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M, Nian H, Mayfield D, Devin J, Gamboa J, Yu C, Silver H, Niswender K, Luther J, Brown N. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes 2023, 73: 38-50. PMID: 37874653, PMCID: PMC10784656, DOI: 10.2337/db23-0356.Peer-Reviewed Original ResearchConceptsEndogenous GLP-1Glucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsImproved insulin sensitivityInsulin sensitivityGLP-1GLP-1RGlucagon levelsGlucose levelsMatsuda indexWeight lossHypocaloric dietPostprandial glucoseInhibitor sitagliptinReceptor agonistMetabolic effectsDiet-induced weight lossDipeptidyl peptidase-4 inhibitor sitagliptinGLP-1R agonist liraglutideWeight loss-independent effectsDPP-4 inhibitor sitagliptinDipeptidyl peptidase-4 inhibitionPeptidase-4 inhibitionMixed meal testGLP-1R antagonist849-P: Antidiabetic Effects of TLC-3595, a Selective ACC2 Inhibitor, in ZDF Rats
VIJAYAKUMAR A, MURAKAMI E, HUSS R, SRODA N, SHIMAZAKI A, KASHIWAGI Y, MYERS R, SUBRAMANIAN M, SHULMAN G. 849-P: Antidiabetic Effects of TLC-3595, a Selective ACC2 Inhibitor, in ZDF Rats. Diabetes 2023, 72 DOI: 10.2337/db23-849-p.Peer-Reviewed Original ResearchZucker diabetic fattyZDF ratsInsulin sensitivityAcetyl-CoA carboxylase 2T2D progressionAntidiabetic effectsClamp glucose infusion rateIntramyocellular lipid contentImproved insulin sensitivityHyperinsulinemic-euglycemic clampType 2 diabetesGlucose infusion rateNovel therapeutic approachesΒ-cell failureFatty acid oxidationFortress BiotechCardiac lipidsInsulin resistanceInfusion rateTherapeutic approachesStrong rationaleRatsGilead SciencesJanssen ResearchIMCL
2017
Summary Points and Consensus Recommendations From the International Protein Summit
Hurt R, McClave S, Martindale R, Gautier J, Coss‐Bu J, Dickerson R, Heyland D, Hoffer L, Moore F, Morris C, Paddon‐Jones D, Patel J, Phillips S, Rugeles S, Sarav M, Weijs P, Wernerman J, Hamilton‐Reeves J, McClain C, Taylor B. Summary Points and Consensus Recommendations From the International Protein Summit. Nutrition In Clinical Practice 2017, 32: 142s-151s. PMID: 28388374, DOI: 10.1177/0884533617693610.Peer-Reviewed Original ResearchConceptsIntensive care unitPhase of critical illnessHigh nutritional riskInitial phase of critical illnessCritically ill patientsHealthcare professionalsMammalian target of rapamycinNutritional riskImproved insulin sensitivityDose of proteinClinical nutritionProtein goalsMuscle massNutrition therapyHigh doses of proteinClinical outcomesProtein administrationTarget of rapamycinBody protein homeostasisSummary PointsMeeting energy goalsHigh dosesNew protein synthesisProtein doseConsensus recommendations
2011
High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction
Carvalho L, Cintra R, Moura F, Martins N, Quinaglia e Silva J, Coelho O, Sposito A, Group O. High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction. Atherosclerosis 2011, 220: 231-236. PMID: 22018645, DOI: 10.1016/j.atherosclerosis.2011.09.044.Peer-Reviewed Original ResearchConceptsHDL-C levelsHDL-C quartilePlasma HDL-C levelsHDL-CC-peptideMyocardial infarctionAcute phaseStress hyperglycemiaInsulin sensitivityAssociated with HDL-C levelsConsecutive non-diabetic patientsNon-diabetic patientsAcute phase of MILow plasma HDL-C levelsAcute phase of myocardial infarctionST-segment elevationPhase of myocardial infarctionBeta-cell functionAssess insulin sensitivityPhase of MIImproved insulin sensitivityBlood glucose changesPlasma glucoseQuartilePlasma insulin
2008
Short‐term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance
Burgert TS, Duran EJ, Goldberg‐Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S. Short‐term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatric Diabetes 2008, 9: 567-576. PMID: 18761646, DOI: 10.1111/j.1399-5448.2008.00434.x.Peer-Reviewed Original ResearchConceptsNormal glucose toleranceInsulin sensitivityGlucose toleranceObese childrenDouble-blind clinical trialType 2 diabetes mellitusSubcutaneous fatCardio-metabolic consequencesBaseline insulin sensitivityImproved insulin sensitivityInsulin-resistant adolescentsHeart rate recoveryLong-term treatmentDeep subcutaneous fatShort-term useMagnetic resonance imagingPlacebo groupCardiovascular effectsDiabetes mellitusMetS groupClinical effectsLipid parametersInsulin sensitizersInflammatory cytokinesObese adolescents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply